Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Private Placement 2024
View:
Post by WarrantOfficer on Jan 16, 2024 9:27am

Private Placement 2024

I do give credit to the fact management completed 2023 with only 1 PP,  but this current PP is a clear indication to me, that full or even partial financing is not even close. I would humbly tip my hat if proven wrong.
Comment by Mork102 on Jan 16, 2024 10:04am
I won't be participating  bought in over 3 years ago and I'm still waiting for something to happen luckily sold some at .25 on HC news and bought back steadily over the last couple of years hoping for FDA approval  this stock is in my TFSA and basically I'm forgetting about it 
Comment by postie1 on Jan 16, 2024 10:12am
Will not even begin to debate you on that
Comment by biggdogg on Jan 16, 2024 11:48am
My take on this, Management waited as long as possible to get next small round in the door, as they could have done this earlier at $0.04. The fact its a small raise indicates to me they are using funds to launch sales and revenue. No point doing large financings with stock at these levels. The fact they are protecting shareholders from dilution is positive, shows they are confident on moving ...more  
Comment by postie1 on Jan 16, 2024 2:37pm
 I do not expect any news other than PP closings before Feb. 8th which is the closing date. What I am wondering is are the powers that be going to run the price up like what happened the last time if you remember?  Sell some and buy back in at a lower price to participate which means it should not cost (TFSA) you anything unless that Taxy guy objects. Did the price not hit 11 or 12 ...more  
Comment by postie1 on Jan 16, 2024 2:38pm
I forgot to add that if it goes up before holding period is over you could end up with fewer shares in the TFSA.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1